secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021886
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q3 revenue $47.8M (+21% YoY); narrows FY2022 revenue guidance to $185-190M
--------------------------------------------------------------------------------

- Q3 2022 revenue $47.8M vs $39.5M in Q3 2021 (+21%); clonoSEQ test volume up 52% YoY.
- Immune Medicine revenue $27.9M (+18% YoY); MRD revenue $20.0M (+26% YoY).
- Net loss improved to $45.3M from $56.0M; adjusted EBITDA loss $25.9M vs $41.1M.
- FY2022 revenue guidance narrowed to $185-190M from $185-195M; opex now expected below $400M.
- Signed $250M non-dilutive royalty financing with OrbiMed; Epic partnership for clonoSEQ EMR integration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017022021886/0000950170-22-021886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017022021886/adpt-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer